


Researchers evaluate effectiveness of placental growth factor measurement in mid-pregnancy

November 14 2023



Credit: MART PRODUCTION from Pexels

A new study led by Professor Laura Magee, has found that among pregnancies with clinical risk factors for pre-eclampsia or fetal growth

restriction, measuring serum placental growth factor (PIGF) at the time of the routine 20-week fetal ultrasound scan is not helpful to inform clinical care pathways. The work is [published](#) in the *BJOG: An International Journal of Obstetrics & Gynaecology*.

Pre-eclampsia and [fetal growth restriction](#) are leading causes of maternal and fetal/newborn mortality and morbidity, here in the U.K. and worldwide. Identifying these pregnancies is a key objective of antenatal care, and national guidance advises that maternity care-providers identify women with clinical risk factors, so that they can be offered enhanced surveillance and/or [low-dose aspirin](#).

However, it is recognized that clinical risk factors are common, and they pick up less than half of pregnancies that end in complications, including gestational hypertension, stillbirth, and prolonged neonatal intensive care unit admission.

As low [serum](#) placental growth factor (PIGF) has been associated with both [pre-eclampsia](#) and fetal growth restriction, this study evaluated whether PIGF could be measured at 19–23 weeks' gestation, in [conjunction](#) with the routine ultrasound assessment for fetal anomalies, as a "contingency screening tool" to improve the predictive performance of clinical risk factors for the subsequent development of pre-eclampsia, fetal growth restriction, or other related complications.

More than 30,000 pregnancies at 19–23 weeks' gestation were screened with PIGF at King's College Hospital and Medway Maritime Hospital. From that [dataset](#), 33% of pregnancies had a clinical risk factor for pre-eclampsia or fetal growth restriction, and they experienced 42%–55% of the adverse outcomes during or after pregnancy.

When PIGF testing at 19–23 weeks' gestation was added in a second step to earlier risk factor screening, a low PIGF was associated with a higher

risk of problems before term gestational age, but these represented

Citation: Researchers evaluate effectiveness of placental growth factor measurement in mid-pregnancy (2023, November 14) retrieved 25 February 2025 from <https://medicalxpress.com/news/2023-11-effectiveness-placental-growth-factor-mid-pregnancy.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.